DRUG — Bright Minds Biosciences Share Price
Last trade - 00:00- CA$6.56m
- -CA$0.15m
- 16
- 32
- 25
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.09 | ||
| Price to Tang. Book | 1.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -112.22% | ||
| Return on Equity | -79.07% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.
Directors
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 31st, 2019
- Public Since
- February 8th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 4,463,837
- Address
- 19 Vestry Street, NEW YORK, 10013
- Web
- https://brightmindsbio.com/
- Phone
- +1 6478658622
- Auditors
- De Visser Gray LLP
Upcoming Events for DRUG
Similar to DRUG
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
As of Today at 19:04 UTC, shares in Bright Minds Biosciences are trading at CA$1.47. This share price information is delayed by 15 minutes.
Shares in Bright Minds Biosciences last closed at CA$1.47 and the price had moved by -65.41% over the past 365 days. In terms of relative price strength the Bright Minds Biosciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -67.39% over the past year.
The overall consensus recommendation for Bright Minds Biosciences is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Bright Minds Biosciences does not currently pay a dividend.
Bright Minds Biosciences does not currently pay a dividend.
Bright Minds Biosciences does not currently pay a dividend.
To buy shares in Bright Minds Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$1.47, shares in Bright Minds Biosciences had a market capitalisation of CA$6.56m.
Here are the trading details for Bright Minds Biosciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: DRUG
Based on an overall assessment of its quality, value and momentum Bright Minds Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bright Minds Biosciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -36.67%.
As of the last closing price of CA$1.47, shares in Bright Minds Biosciences were trading -64.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bright Minds Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bright Minds Biosciences' management team is headed by:
- Ian McDonald - PRE
- Ryan Cheung - CFO
- Alan Kozikowski - CSO
- Nils Bottler - IND
- Jeremy Fryzuk - IND